AXSM News and Press, Axsome Therapeutics Inc. From 10/05/22

Summary Despite the recent downtrend in its trading, Axsome Therapeutics, Inc.'s fundamentals are stronger than ever. Asides from the Sunosi acquisition, the company recently gained Auvelity approval to treat major depressive disorder. Interestingly, the latest Type A meeting ...

Axsome Therapeutics ( NASDAQ: AXSM ) added ~7% pre-market Monday after the company announced its FDA-approved therapy for excessive daytime sleepiness (EDS) Sunosi improved the cognitive function of patients in a placebo-controlled study. The dopamine and norepinephrine ...

Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint) Statistically significant patient-reported improvement in cognitive function, as measured by the BC-CCI compared to placebo (p=0.002) ...

Axsome Therapeutics ( NASDAQ: AXSM ) announced Thursday its plans to resubmit a New Drug Application (NDA) for migraine therapy AXS-07 to the FDA in Q3 2023. The decision follows a Type A meeting AXSM held with the regulator to obtain FDA feedback and its agreement on its ...

NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that, following a Type A meeting with the U.S. Food and Drug A...

Think of the biggest, richest corporations on the planet. They all started out much smaller but grew enormously over time. Investors who spotted their potential early on made fortunes. We asked three Motley Fool contributors to pick monster stocks in the making that just might make inve...

Biotech company Axsome Therapeutics (NASDAQ: AXSM) has been one of the hottest stocks this year, rising 36% in value. That's particularly impressive given that the stock market is down and the S&P 500 has declined by 20% so far in 2022 as of this writing. Bolstered by the Fo...

The bear market hasn't dragged down Axsome Therapeutics (NASDAQ: AXSM) . The biotech company specializes in treating central nervous system conditions. And it's been on a roll with good news -- and share performance -- in recent weeks. Axsome has climbed 167% from a low in June. Tha...

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executi...

Biotech companies with few products on the market and red ink on the bottom line may not look like the most attractive investments right now. Equity markets are still down substantially year-to-date, and in this environment investors prefer putting their money in safer stocks. But for t...